Zilucoplan (TFA)

• UNSPSC Description:

  Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM)[1][2].

• Target Antigen:

  Complement System

• Type:

  Peptides

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/zilucoplan-tfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCCCCCCCCCCCCCC(N[C@H](C(O)=O)CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](NC([C@@H](NC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N(C([C@@H]2CC(NCCCC[C@H](NC(C)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC3=CC=CC=C3)C(N2)=O)=O)=O)=O)=O)=O)=O)C)CC(O)=O)=O)C(C)(C)C)=O)CC4=CC=C(O)C=C4)=O)CC5=CNC6=C5C=CC=N6)=O)CCC(O)=O)=O)CC7=CC=C(O)C=C7)=O)=O)C8CCCCC8)=O)C(O)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]

• Molecular Weight:

  3562.18 (free base)

• References & Citations:

  [1]Julien S, et, al. Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model. Biomedicines. 2022 Aug 20;10(8):2036.|[2]Gorman DM, et, al. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids. 2021 Jan;53(1):143-147.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched